ever
sinc
singapor
stricken
march
sever
acut
respiratori
syndrom
sar
becam
appar
mani
survivor
experienc
chronic
pulmonari
morbid
multitud
psychosomat
manifest
hypothes
endocrinolog
basi
could
account
extrapulmonari
symptom
due
resembl
variou
hormon
metabol
disord
frequent
featur
nonspecif
symptomatolog
studi
link
aberr
hpa
axi
psychiatr
condit
moreov
correl
hpt
axi
dysfunct
certain
psychosomat
syndrom
describ
primari
focu
prospect
studi
determin
exist
chronic
hpa
axi
sequela
sar
survivor
character
prognost
outcom
presenc
hpt
axi
dysfunct
constitut
secondari
object
given
endocrinopath
properti
coronaviru
current
inadequ
explor
domain
hormon
aberr
unravel
preliminari
investig
contribut
new
scientif
insight
medic
databas
potenti
translat
clinic
relev
therapeut
strategi
endocrinopathi
research
conduct
tan
tock
seng
hospit
nation
design
infirmari
isol
treatment
sar
patient
approv
institut
review
board
total
infect
sar
die
survivor
probabl
sar
singapor
age
year
elig
endocrin
disord
sar
exclud
survivor
two
underli
primari
hypothyroid
exclud
fulfil
inclus
criteria
provid
written
inform
consent
prospect
enrol
month
postdischarg
last
batch
patient
enter
studi
septemb
follow
till
octob
remain
survivor
recruit
consent
varieti
person
reason
mani
cite
inconveni
inabl
follow
extend
period
year
reluct
subject
laboratori
investig
number
survivor
refus
particip
ground
psycholog
unprepar
state
grief
deceas
rel
expir
sar
remain
noncontact
could
recruit
sever
underag
individu
exclud
purpos
studi
use
admiss
intens
care
unit
icu
arbitrari
criterion
sever
sar
sever
sar
case
admit
icu
surviv
among
eight
sever
sar
subject
enrol
declin
particip
thu
among
survivor
sever
sar
recruit
recruit
subject
sever
sar
repres
studi
cohort
enter
studi
blood
sampl
collect
h
venepunctur
edta
plain
tube
full
blood
count
electrolyt
cortisol
acth
free
free
tsh
dehydroepiandrosteron
sulphat
dhea
urinari
free
cortisol
ufc
done
assess
integr
cortisol
secret
subject
serum
cortisol
nmoll
underw
dynam
hpa
axi
evalu
use
low
dose
short
synacthen
test
sst
subject
h
serum
cortisol
nmoll
andor
poststimul
serum
cortisol
nmoll
min
deem
hypocortisol
sst
assess
hpa
axi
recoveri
repeat
three
six
monthli
interv
although
studi
termin
year
review
extend
persist
hypocortisol
medic
appropri
symptomat
patient
orthostat
hypotens
prescrib
physiolog
dose
hydrocortison
replac
sst
normal
blood
centrifug
plasma
separ
frozen
store
assay
hormon
measur
techniqu
includ
immunochemiluminometr
assay
icma
radioimmunoassay
ria
immunoradiometr
assay
irma
employ
accord
standard
manufactur
protocol
detect
limit
interassay
coeffici
variat
publish
packag
insert
chemiluminesc
analys
diagnost
corp
medfield
tsh
gener
tsh
assay
sanofi
diagnost
pasteur
inc
chaska
mn
dickinson
co
kit
smithklin
beecham
laboratori
van
nuy
ca
dhea
kit
diagnost
product
corp
la
ca
cortisol
solid
phase
product
corp
la
ca
acth
immunoradiometr
assay
nichol
institut
diagnost
san
juan
capistrano
ca
ufc
measur
enhanc
chemiluminesc
immunoassay
use
vitro
eci
immunodiagnost
analys
descript
statist
analysi
perform
raw
data
applic
stimul
cortisol
sequenti
assess
pair
numer
data
compar
use
nonparametr
wilcoxon
sign
rank
test
p
valu
less
use
criterion
indic
statist
signific
analysi
done
use
spss
statist
softwar
packag
person
comput
version
institut
review
board
research
ethic
committe
tan
tock
seng
hospit
approv
studi
basi
compli
declar
helsinki
protocol
follow
exist
good
clinic
practic
guidelin
tabl
show
demograph
clinic
profil
studi
popul
patient
hypocortisol
unequivoc
central
hypocortisol
evidenc
concomit
low
inappropri
normal
acth
level
tabl
four
hypocortisol
associ
plasma
acth
upper
refer
limit
pmoll
pgml
although
may
superfici
suggest
primari
hypocortisol
level
acth
elev
suffici
diagnost
primari
hypocortisol
absenc
data
overt
addisonian
crisi
primari
adren
insuffici
unlik
wherea
secondari
hypocortisol
appear
main
form
hpa
axi
dysfunct
encount
inde
rais
acth
may
fact
reflect
recov
hpa
axi
follow
suppress
among
four
patient
one
given
system
steroid
sar
probabl
case
central
hypocortisol
rather
primari
hypocortisol
recruit
time
unit
recov
transient
hpa
axi
suppress
three
elev
acth
steroid
exposur
sar
prior
sar
could
arguabl
case
central
hypocortisol
show
evid
earli
recoveri
rather
primari
adren
insuffici
among
patient
hypocortisol
three
deem
hypocortisol
base
h
serum
cortisol
nmoll
patient
borderlin
valu
underw
sst
evalu
hpa
axi
integr
treatment
protocol
critic
ill
sar
patient
manag
icu
includ
use
system
glucocorticoid
hpa
axi
suppress
caus
central
hypocortisol
exogen
steroid
exposur
remain
possibl
patient
hypocortisol
six
receiv
system
glucocorticoid
sar
one
asthmat
inhal
corticosteroid
among
six
patient
treat
system
glucocorticoid
three
prednisolon
dose
mg
given
day
three
patient
intraven
methylprednisolon
mg
day
follow
hydrocortison
mg
hourli
week
switch
oral
prednisolon
taper
day
notabl
major
patient
hypocortisol
glucocorticoid
four
six
patient
treat
parenter
glucocorticoid
escap
hypocortisol
demonstr
lack
prolong
suppress
hpa
axi
corticosteroid
regimen
dose
util
support
notion
none
studi
subclin
impair
hpa
axi
retrospect
data
standard
sst
perform
prior
administr
glucocorticoid
reveal
min
stimul
serum
cortisol
exceed
nmoll
critic
ill
case
icu
tabl
indic
intact
hpa
axi
time
acquir
sar
corrobor
measur
determin
hypocortisol
occur
acut
sar
patient
without
sst
data
retrospect
data
blood
pressur
record
height
febril
period
compar
apyrexi
phase
discharg
assum
patient
acut
hypocortisol
develop
midst
sar
would
manifest
profound
hypotens
howev
averag
decreas
mean
arteri
pressur
map
modest
compar
group
hypocortisol
mmhg
n
remain
eucortisol
mmhg
n
use
poststimul
serum
cortisol
greater
nmoll
complet
recoveri
hpa
axi
resolv
within
year
parallel
resolut
orthostat
hypotens
subject
sens
improv
ie
reduc
fatigu
postur
dizzi
compar
perceiv
symptom
time
enter
studi
six
residu
hypocortisol
one
still
requir
hydrocortison
replac
although
formal
evalu
spectrum
symptom
normal
vs
impair
hpa
axi
use
standard
psychometr
scale
instrument
health
outcomesqu
life
qol
measur
eg
normal
hpa
axi
compar
impair
hpa
axi
volunt
experienc
fatigu
andor
orthostat
dizzi
point
recruit
serial
sst
reveal
statist
signific
improv
stimul
cortisol
among
hypocortisol
patient
time
p
tabl
four
patient
suboptim
stimul
cortisol
default
whose
hpa
axi
resolv
complet
within
year
averag
durat
recoveri
hypofunct
hpa
axi
month
among
patient
delay
recoveri
hpa
axi
beyond
month
obviou
linkag
age
sex
race
sever
ill
howev
clear
trend
improv
cours
stimul
adren
cortisol
output
case
hypocortisol
fig
two
hypocortisol
cohort
subclin
thyrotoxicosi
four
biochem
hypothyroid
compris
three
central
hypothyroid
one
primari
hypothyroid
thyroid
autoantibodi
posit
male
patient
primari
hypothyroid
antithyroglobulin
antibodi
posit
antithyroperoxidas
antibodi
miuml
though
neither
previou
symptom
histori
thyroid
disord
two
three
central
hypothyroid
concomit
central
hypocortisol
except
patient
primari
hypothyroid
never
recov
still
requir
daili
replac
close
studi
case
thyroid
dysfunct
transient
resolv
month
found
low
level
dhea
eight
patient
adjust
age
sex
menopaus
statu
within
group
male
rest
women
sar
novel
infect
signific
morbid
mortal
pose
seriou
threat
mankind
new
millennium
observ
survivor
sar
clinic
reveal
cluster
chronic
extrapulmonari
symptom
lethargi
malais
lassitud
fatigu
weak
orthostat
dizzi
anorexia
apathi
anxieti
depress
although
mostli
vagu
nonspecif
symptom
reminisc
complaint
seen
host
endocrin
disord
includ
hypothyroid
hypocortisol
thyrotoxicosi
hypercalcaemia
hypopituitar
cush
syndrom
theoret
coronaviru
involv
organ
viraem
phase
certain
form
hypophys
thyroid
adren
viral
aetiolog
instruct
determin
endocrinopath
impact
recent
research
examin
pulmonari
psycholog
aftermath
sar
survivor
howev
studi
limit
longitudin
data
knowledg
endocrin
derang
report
thu
far
investig
set
record
unpreced
effort
chronicl
natur
histori
endocrin
dysfunct
particular
hpa
axi
sar
survivor
year
serial
longitudin
evalu
facilit
character
trend
prognost
sizeabl
proport
surprisingli
exhibit
cortisol
defici
rather
hpa
axi
thyroid
statu
typic
depress
panic
disord
respect
cortisol
disturb
observ
analog
report
chronic
fatigu
syndrom
stress
disord
primari
fibromyalgia
syndrom
wherebi
hpa
axi
appear
central
hypocortisol
consequ
patholog
effect
sar
rather
hpa
axi
suppress
suggest
absenc
steroid
use
nearli
group
moreov
transient
minim
suppress
effect
hpa
axi
glucocorticoid
regimen
use
back
preserv
normal
respons
sst
despit
receiv
glucocorticoid
taken
togeth
impli
hpa
axi
impair
probabl
delay
patholog
complic
rather
mere
ascrib
suppress
exogen
steroid
use
mild
reduct
map
pyrexia
sar
absenc
overt
hypotens
acut
febril
phase
sar
survivor
develop
hypocortisol
subsequ
also
suggest
hypocortisol
phenomenon
support
evid
intact
hpa
axi
standard
dose
sst
acut
sar
subsequ
reveal
impair
hpa
axi
low
dose
sst
month
postdischarg
although
specul
overal
data
interpret
consist
hypothesi
hypocortisol
sar
survivor
develop
gradual
late
complic
sever
week
onset
sar
infect
major
patient
young
mean
age
year
previous
healthi
prior
corticosteroid
exposur
strong
likelihood
aetiolog
agent
respons
hypocortisol
address
integr
hpa
axi
sar
survivor
postdischarg
sst
employ
deem
potenti
appropri
sensit
sst
detect
recent
onset
central
hypocortisol
associ
minim
adren
atrophi
fals
neg
could
result
supraphysiolog
sst
neg
thyroid
autoantibodi
one
patient
implic
rather
autoimmun
pathogenet
mechan
caus
transient
subclin
thyrotoxicosi
hypothyroid
nonthyroid
ill
ie
euthyroid
sick
syndrom
unlik
confound
patient
complet
apyrexi
time
enrol
studi
although
radionuclid
scan
thyroid
biopsi
perform
postul
induc
thyroid
hypophys
either
alon
combin
probabl
reason
thyroid
dysfunct
assay
dhea
evid
medic
literatur
suggest
correl
low
dhea
level
psychosomat
symptom
howev
found
much
smaller
number
dhea
defici
compar
hypocortisol
find
may
explain
fact
adren
androgen
product
sole
regul
acth
also
peptid
includ
neuroimmun
system
possibl
dhea
replac
could
amelior
symptom
dhea
defici
dramat
improv
energi
level
mood
resolut
dizzi
achiev
satisfactori
cortisol
level
dhea
replac
institut
affect
predominantli
femal
patient
case
advers
effect
outweigh
benefit
elect
investig
rest
pituitari
hormon
focu
attent
hpa
axi
thyroid
dysfunct
better
defin
postvir
syndrom
although
suggest
cours
clinic
patient
impair
hpa
axi
rel
symptomat
initi
compar
year
later
formal
correl
endocrin
dysfunct
psychosomat
symptom
permit
rigor
conclus
whether
subject
impair
hpa
axi
symptom
intact
hpa
axi
symptom
significantli
improv
recoveri
treatment
intriguingli
link
exist
may
mediat
enzym
ace
possibl
interact
neurotransmitt
pathway
yet
understood
regard
alter
insertiondelet
id
polymorph
ace
gene
associ
increas
risk
chronic
fatigu
syndrom
idiopath
chronic
fatigu
coincident
util
lectin
surfac
glycoprotein
call
critic
portal
cellular
entri
perhap
andor
could
express
hypothalamu
pituitari
may
play
role
fatigu
pathogenesi
given
data
hypocortisol
even
though
neither
shown
date
express
endocrin
organ
final
overal
prognosi
hypocortisol
survivor
appear
favour
result
provid
compel
evid
hpa
hpt
axe
candid
target
pend
futur
sar
epidem
adequ
power
clinic
studi
clarifi
could
prove
daunt
vitro
studi
anim
model
sar
might
better
defin
endocrin
lesion
overal
data
seem
consist
sar
caus
revers
hypophys
direct
hypothalam
effect
hpa
axi
frequent
perturb
hpt
axi
sar
survivor
although
specul
find
highlight
possibl
aetiolog
role
endocrinopath
factor
deserv
futur
elucid
vitro
anim
clinic
studi
